


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Previously Presented)

A compound of formula I



wherein

R¹ is H, OH, OA, CN, Hal, COR or CH₂R,

R is OH, OA, NH₂, NHA or NA₂,

R² and R³ are H or A,

A is an alkyl group with 1–10 atoms,

X is O or S,

Hal is F, Cl, Br or I

n is 2-6,

m is 1-4

p is 0, 1, 2, 3 or 4

or a salt, enantiomer, solvate, racemate or mixture of enantiomers thereof.






Claim 2. **(Previously Presented)** A compound according to claim 1, wherein R¹ is F or CN.

Claim 3. **(Previously Presented)** A compound according to claim 1, wherein R³ is H.

Claim 4. **(Canceled)**

Claim 5. **(Canceled)**

Claim 6. **(Previously Presented)** A compound according to claim 1 of the formula I1 to I5:



or a salt, solvate, enantiomer or racemate thereof.

Claim 7. (Previously Presented) A pharmaceutical composition comprising a formula I according to Claim 1 or physiologically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier.

Claims 8. – 14. (Canceled)

Claim 15. (Currently Amended) A method for the treatment of cerebral stroke,
cerebral ischaemia, overexcitation, hyperactivity, attention disorder, deep-seated development
disorder, mental retardation, depression, compulsive disorder, sleep disorders, sexual
disorders, eating disorders, senile dementia or Alzheimer's dementia, schizophrenia, or for the
control of psychotic anxiety states, comprising administering to a host in need thereof a
compound according to claim 1 or a salt, solvate, enantiomer or mixture thereof.